NCT07030907

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

TERMINATEDPHASE1INTERVENTIONAL

Trial Details

Start: 2025-06-16Est. Completion: 2026-09-30

Enrollment target: 3 participants

Locations

Karmanos Cancer Institute, Detroit, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
Roswell Park, Buffalo, New York, United States
MD Anderson Cancer Center, Houston, Texas, United States

Other microbiome trials you might be interested in

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal CancerPhase 1Recruiting

FIGO Stage IVA Ovarian CancerFIGO Stage IVB Ovarian CancerPlatinum-Resistant Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus CarcinomaStage III Fallopian Tube Cancer AJCC v7Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage III Uterine Corpus Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.